Abstract

Increased natural killer cells and decreased CD3<sup>+</sup>CD8<sup>+</sup>CD62L<sup>+</sup> T cells in CML patients who sustained complete molecular remission after discontinuation of imatinib

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call